

# Whitney W Stevens

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3644803/publications.pdf>

Version: 2024-02-01

61  
papers

3,157  
citations

186265

28  
h-index

161849

54  
g-index

71  
all docs

71  
docs citations

71  
times ranked

2835  
citing authors

#	ARTICLE	IF	CITATIONS
1	Endotypes of chronic rhinosinusitis: Relationships to disease phenotypes, pathogenesis, clinical findings, and treatment approaches. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 812-826.	5.7	90
2	Yardstick for the medical management of chronic rhinosinusitis. <i>Annals of Allergy, Asthma and Immunology</i> , 2022, 128, 118-128.	1.0	11
3	Delayed angioedema after administration of the severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine. <i>Annals of Allergy, Asthma and Immunology</i> , 2022, 128, 215-216.	1.0	5
4	Controversies in Allergy: Aspirin Desensitization or Biologics for Aspirin-Exacerbated Respiratory Disease—How to Choose. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1462-1467.	3.8	12
5	Studies on activation and regulation of the coagulation cascade in chronic rhinosinusitis with nasal polyps. <i>Journal of Allergy and Clinical Immunology</i> , 2022, , .	2.9	2
6	Prognostic factors for polyp recurrence in chronic rhinosinusitis with nasal polyps. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 150, 352-361.e7.	2.9	39
7	Anti-εphospholipid antibodies are elevated and functionally active in chronic rhinosinusitis with nasal polyps. <i>Clinical and Experimental Allergy</i> , 2022, 52, 954-964.	2.9	4
8	Use of intraoperative frontal sinus mometasone-eluting stents decreased interleukin 5 and interleukin 13 in patients with chronic rhinosinusitis with nasal polyps. <i>International Forum of Allergy and Rhinology</i> , 2022, 12, 1330-1339.	2.8	4
9	Elevation of activated neutrophils in chronic rhinosinusitis with nasal polyps. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1666-1674.	2.9	28
10	Efficacy of an oral CRTH2 antagonist (AZD1981) in the treatment of chronic rhinosinusitis with nasal polyps in adults: A randomized controlled clinical trial. <i>Clinical and Experimental Allergy</i> , 2022, 52, 859-867.	2.9	9
11	Activation of the 15-lipoxygenase pathway in aspirin-exacerbated respiratory disease. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 600-612.	2.9	43
12	Group 2 innate lymphoid cells in nasal polyposis. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 126, 110-117.	1.0	19
13	The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: AAWork Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunology. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 827-844.	2.9	69
14	Mechanisms and biomarkers of inflammatory endotypes in chronic rhinosinusitis without nasal polyps. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 1306-1317.	2.9	63
15	Biology and Function of Eosinophils in Chronic Rhinosinusitis With or Without Nasal Polyps. <i>Allergy, Asthma and Immunology Research</i> , 2021, 13, 8.	2.9	36
16	Legends of allergy and immunology: Robert P. Schleimer. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3230-3232.	5.7	0
17	Innate immune cell dysregulation drives inflammation and disease in aspirin-exacerbated respiratory disease. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 309-318.	2.9	12
18	Studies of the role of basophils in aspirin-exacerbated respiratory disease pathogenesis. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 439-449.e5.	2.9	20

#	ARTICLE	IF	CITATIONS
19	Prevalence of Bronchiectasis in Patients with Chronic Rhinosinusitis in a Tertiary Care Center. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3188-3195.e2.	3.8	12
20	Impact of type 2 targeting biologics on acute exacerbations of chronic rhinosinusitis. <i>Allergy and Asthma Proceedings</i> , 2021, 42, 417-424.	2.2	9
21	COVID-19 vaccine-related presumed allergic reactions and second dose administration by using a two-step graded protocol. <i>Allergy and Asthma Proceedings</i> , 2021, 42, 515-521.	2.2	15
22	TNF induces production of type 2 cytokines in human group 2 innate lymphoid cells. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 437-440.e8.	2.9	6
23	Role of RANK-L as a potential inducer of ILC2-mediated type 2 inflammation in chronic rhinosinusitis with nasal polyps. <i>Mucosal Immunology</i> , 2020, 13, 86-95.	6.0	25
24	Use of endotypes, phenotypes, and inflammatory markers to guide treatment decisions in chronic rhinosinusitis. <i>Annals of Allergy, Asthma and Immunology</i> , 2020, 124, 318-325.	1.0	79
25	Development and Preliminary Validation of a New Patient-Reported Outcome Measure for Chronic Rhinosinusitis (CRS-PRO). <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2341-2350.e1.	3.8	15
26	Decreased nasal polyp eosinophils but increased mast cells in a patient with aspirin-exacerbated respiratory disease treated with reslizumab. <i>Annals of Allergy, Asthma and Immunology</i> , 2020, 125, 490-493.e2.	1.0	4
27	Integrin $\alpha$ 26 microparticles in nasal lavage fluids; potential new biomarkers for basal cell activation in chronic rhinosinusitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 3261-3264.	5.7	6
28	Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 307-314.e4.	2.9	240
29	Responsiveness and Convergent Validity of a New Patient-Reported Outcome Measure for Chronic Rhinosinusitis (CRS-PRO). <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2351-2359.e2.	3.8	10
30	Clinical factors associated with acute exacerbations of chronic rhinosinusitis. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 1598-1605.	2.9	16
31	Associations Between Inflammatory Endotypes and Clinical Presentations in Chronic Rhinosinusitis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2812-2820.e3.	3.8	221
32	Sinus Infections, Inflammation, and Asthma. <i>Immunology and Allergy Clinics of North America</i> , 2019, 39, 403-415.	1.9	11
33	Prevalence and characterization of chronic rhinosinusitis in patients with non $\alpha$ cystic fibrosis bronchiectasis at a tertiary care center in the United States. <i>International Forum of Allergy and Rhinology</i> , 2019, 9, 1424-1429.	2.8	19
34	Increased thrombin-activatable fibrinolysis inhibitor levels in patients with chronic rhinosinusitis with nasal polyps. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 1566-1574.e6.	2.9	20
35	A new treatment for chronic rhinosinusitis with nasal polyps. <i>Lancet, The</i> , 2019, 394, 1595-1597.	13.7	5
36	Clinical Characteristics of Patients with Chronic Rhinosinusitis without Nasal Polyps in an Academic Setting. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1010-1016.	3.8	73

#	ARTICLE	IF	CITATIONS
37	Asthma onset pattern and patient outcomes in a chronic rhinosinusitis population. <i>International Forum of Allergy and Rhinology</i> , 2018, 8, 495-503.	2.8	36
38	IL-10, TGF- $\beta$ 2, and glucocorticoid prevent the production of type 2 cytokines in human group 2 innate lymphoid cells. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 1147-1151.e8.	2.9	40
39	Epithelial activators of type 2 inflammation: Elevation of thymic stromal lymphopoietin, but not IL-25 or IL-33, in chronic rhinosinusitis with nasal polyps in Chicago, Illinois. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 2251-2254.	5.7	37
40	Proprotein convertases generate a highly functional heterodimeric form of thymic stromal lymphopoietin in humans. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1559-1567.e8.	2.9	27
41	Clinical Characteristics of Patients with Chronic Rhinosinusitis with Nasal Polyps, Asthma, and Aspirin-Exacerbated Respiratory Disease. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 1061-1070.e3.	3.8	162
42	Microparticles in nasal lavage fluids in chronic rhinosinusitis: Potential biomarkers for diagnosis of aspirin-exacerbated respiratory disease. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 720-729.	2.9	31
43	Group 2 innate lymphoid cells are elevated and activated in chronic rhinosinusitis with nasal polyps. <i>Immunity, Inflammation and Disease</i> , 2017, 5, 233-243.	2.7	105
44	Evidence for altered levels of IgD in the nasal airway mucosa of patients with chronic rhinosinusitis. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 1562-1571.e5.	2.9	24
45	Classical complement pathway activation in the nasal tissue of patients with chronic rhinosinusitis. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 89-100.e2.	2.9	36
46	A prospective analysis evaluating tissue biopsy location and its clinical relevance in chronic rhinosinusitis with nasal polyps. <i>International Forum of Allergy and Rhinology</i> , 2017, 7, 1058-1064.	2.8	18
47	Proton pump inhibitors decrease eotaxin-3/CCL26 expression in patients with chronic rhinosinusitis with nasal polyps: Possible role of the nongastric H,K-ATPase. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 130-141.e11.	2.9	63
48	Heterogeneous inflammatory patterns in chronic rhinosinusitis without nasal polyps in Chicago, Illinois. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 699-703.e7.	2.9	140
49	Reply. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 1808-1809.	3.8	1
50	Chronic Rhinosinusitis with Nasal Polyps. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2016, 4, 565-572.	3.8	285
51	Aspirin-Exacerbated Respiratory Disease as an Endotype of Chronic Rhinosinusitis. <i>Immunology and Allergy Clinics of North America</i> , 2016, 36, 669-680.	1.9	39
52	African American Patients with Chronic Rhinosinusitis Have a Distinct Phenotype of Polyposis Associated with Increased Asthma Hospitalization. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2016, 4, 658-664.e1.	3.8	25
53	Immunodeficiency in Chronic Sinusitis: Recognition and Treatment. <i>American Journal of Rhinology and Allergy</i> , 2015, 29, 115-118.	2.0	35
54	Chronic rhinosinusitis pathogenesis. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 1442-1453.	2.9	270

#	ARTICLE	IF	CITATIONS
55	Increased noneosinophilic nasal polyps in chronic rhinosinusitis in US second-generation Asians suggest genetic regulation of eosinophilia. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 576-579.	2.9	94
56	Cytokines in Chronic Rhinosinusitis. Role in Eosinophilia and Aspirin-exacerbated Respiratory Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 682-694.	5.6	224
57	Expression of ligands for Siglec-8 and Siglec-9 in human airways and airway cells. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 799-810.e7.	2.9	54
58	Aspirin-Exacerbated Diseases: Advances in Asthma with Nasal Polyposis, Urticaria, Angioedema, and Anaphylaxis. <i>Current Allergy and Asthma Reports</i> , 2015, 15, 69.	5.3	20
59	Occupational Rhinitis: an Update. <i>Current Allergy and Asthma Reports</i> , 2015, 15, 487.	5.3	30
60	Basophils are elevated in nasal polyps of patients with chronic rhinosinusitis without aspirin sensitivity. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 1759-1763.	2.9	80
61	Biology of nasal polyposis. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 1503-1503.e4.	2.9	29